Laboratorio Reig Jofre SA
MAD:RJF
Net Margin
Laboratorio Reig Jofre SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| ES |
|
Laboratorio Reig Jofre SA
MAD:RJF
|
219.4m EUR |
3%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
696.3B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
370.4B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
199.9B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
181.5B CHF |
23%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
156.8B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
193.6B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
-126%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
112B EUR |
13%
|
Laboratorio Reig Jofre SA
Glance View
Laboratorio Reig Jofre SA engages in the research, development, manufacture, and trade of pharmaceutical drugs. The company is headquartered in Sant Joan Despi, Barcelona and currently employs 1,152 full-time employees. The company went IPO on 2006-11-07. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The firm also provides nutritional cosmetics, and food supplements, among others. The company operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Laboratorio Reig Jofre SA's most recent financial statements, the company has Net Margin of 3.1%.
You don't have any saved screeners yet